Tag Archives: Phase III

Discovery of Rivaroxaban (Factor Xa Inhibitor)

Posted on January 14, 2011 by mcb

The discovery of novel anticoagulants, and the search for novel orally active agents in particular, has been a long and difficult journey.  However, the recent (2008) launches of Bayer’s Factor Xa inhibitor (Rivaroxaban, BAY 59-7939) and Boehringer Ingelheim’s Thrombin inhibitor … Continue reading →

Posted in Enzyme Inhibitors, Launched Drugs | Tagged , , , , , , , , , , , , | 1 Comment

The Discovery of RG1678 (Gly-T1 inhibitor)

Posted on July 20, 2010 by mcb

In this interesting J.Med.Chem. article workers from Roche describe the optimisation of a series of benzoylpiperazines as Gly-T1 inhibitors for the treatment of schizophrenia culminating in the discovery of RG1678, the first potent and selective Gly-T1 inhibitor to demonstrate efficacy … Continue reading →

Posted in Clinical Candidates, Transporter Modulator | Tagged , , , , , , , , , | Leave a comment